Monday, August 31, 2026 SourcesAbout🌓
🇺🇸 US ▾
BREAKING
Business

BioCryst is profitable. Now it wants to buy more rare disease drugs

CNBC ·

Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.

Read the full article on CNBC ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.cnbc.com — the content belongs to CNBC.

More from CNBC

See all ›

More in Business

See all ›